Health
Phico Therapeutics awarded up to $18.2 million USD (c.£13.2 million GBP) CARB-X funding to advance SASPject antibacterial therapy through Phase 1 clinical trials – News-Medical.net
Phico Therapeutics has been awarded a grant of up to $18.2 million USD to tackle the global rising threat of drug-resistant bacteria.
Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has been awarded a grant of up to $18.2 million USD (circa. £13.2 million GBP) from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
Phico Therapeutics…
-
Noosa News19 hours agoToombul Shopping Centre site thrown lifeline after Mirvac announces sale with ‘priority’ to build new retail centre
-
General20 hours agoAllegations against ex-Attorney-General Mark Dreyfus removed from Linda Reynolds action against Commonwealth
-
General8 hours agoDriver charged after fatal alleged hit-run crash at Hillier
-
Noosa News22 hours agoMirvac to sell site to Irvine Group